1. MYC expression is correlated with dasatinib sensitivity in cancer cell lines and in vivo.
MYC expression is correlated with dasatinib sensitivity in cancer cell lines and in vivo. A, relationship between dasatinib sensitivity as determined in this study and published MYC gene expression data across 664 cancer cell lines (2). An AUC < 3 is used to define sensitive cell lines. B and C, relationship between dasatinib sensitivity and MYC expression as assessed through RNAseq (B) and reverse-phase protein array (RPPA; C) data from breast cancer cell lines published in ref. 54. D, MYC protein levels assessed by Western blot analysis across established breast cancer cell lines. E, relative viability of breast cancer cell lines across a range of concentrations of dasatinib. F, percentage change in tumor volume of human cell lines xenografted into mice and treated daily with the indicated concentration of dasatinib via oral gavage. A minimum of 5 mice were used in each group. n.s., not significant.
Maria M. Martins et al. Cancer Discov 2015;5:
©2015 by American Association for Cancer Research